Top

Diagnostic Pathology

Published in:

Open Access 01-12-2016 | Research

Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma

Authors: Li Wang, Huanwen Wu, Lili Wang, Junliang Lu, Huanli Duan, Xuguang Liu, Zhiyong Liang

Published in: Diagnostic Pathology | Issue 1/2016

Abstract

Background

The validation of novel diagnostic, prognostic and predictive biomarkers in cancer is crucial for optimizing the choice and efficacy of personalized therapies. The aim of this study was to determine the epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII) and amphiregulin (AREG) protein expression levels and to evaluate the prognostic significance of EGFR, EGFRvIII and AREG in pancreatic ductal adenocarcinoma (PDAC).

Methods

The EGFR, EGFRvIII and AREG protein levels in PDAC (n = 92) were examined by using immunohistochemistry. The associations between EGFRvIII expression, AREG expression, AREG/EGFR co-expression and clinicopathological factors were assessed, the correlation between AREG and EGFR expression was analyzed and the survival analyses were performed.

Results

Among the lesions of PDAC, 12 (13 %) stained positive for EGFRvIII, 49 (53.3 %) stained positive for AREG and 22(23.9 %) stained double positive for AREG/EGFR. The relationships between each protein expression level and the clinicopathologic factors were examined, only AREG/EGFR co-expression was significantly related to tumor differentiation (P = 0.032). The correlation between AREG and EGFR expression was statistically insignificant (P = 0.709). Univariate survival analysis proved that high tumor-node-metastasis (TNM) stage, poor tumor differentiation and AREG expression were significant poor prognostic factors for disease-free survival (DFS) and overall survival (OS). By multivariate survival analysis, tumor differentiation was an independent poor prognostic factor for DFS (HR = 1.785, P < 0.05), whereas high TNM stage (HR = 2.25, P < 0.05), poor tumor differentiation (HR = 2.125, P < 0.01), positive resection margins (HR = 1.84, P < 0.05), and AREG expression (HR = 1.822, P < 0.05) were all independent poor prognostic factors for OS.

Conclusions

In conclusion, our data indicate that AREG expression is an important prognostic biomarker in PDAC .

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21254.CrossRefPubMed

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. doi:10.3322/caac.21338. Epub 2016 Jan 25.CrossRefPubMed

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.CrossRefPubMed

Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7 Suppl 4:31–9. doi:10.1634/theoncologist.7-suppl_4-31.CrossRefPubMed

Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16:748–54. doi:10.1016/j.jocn.2008.12.005.CrossRefPubMed

Gan HK, Burgess AW, Clayton AHA, Scott AM. Targeting of a conformationally exposed, tumor-specific Epitope of EGFR as a strategy for cancer therapy. Cancer Res. 2012;72(12):2924–30. doi:10.1158/0008-5472.CAN-11-3898.CrossRefPubMed

Berasain C, Avila MA. Amphiregulin. Semin Cell Dev Biol. 2014;28:31–41. doi:10.1016/j.semcdb.2014.01.005.CrossRefPubMed

Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011;1816(2):119–31. doi:10.1016/j.bbcan.2011.05.003.PubMed

Yamada M, Ichikawa Y, Yamagishi S, Momiyama N, Ota M, Fujii S, et al. Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res. 2008;14:2351–6. doi:10.1158/1078-0432.CCR-07-4499.CrossRefPubMed

10.

Tinhofer I, Klinghammer K, Weichert W, Knodler M, Stenzinger A, Gauler T, et al. Expression of Amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving Cetuximab–Docetaxel treatment. Clin Cancer Res. 2011;17:5197–204. doi:10.1158/1078-0432.CCR-10-3338.CrossRefPubMed

11.

Park JK, Kim MA, Ryu JK, Yoon YB, Kim S, Han H, et al. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Ann Surg Oncol. 2012;19:2664–72. doi:10.1245/s10434-012-2277-7.CrossRefPubMed

12.

Wu H, Zhu L, Zhang H, Shi X, Zhang L, Wang W, et al. Co-expression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. PLoS One. 2015;10:e0116803.CrossRefPubMedPubMedCentral

13.

Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63(20):6962–70.PubMed

14.

Nagathihalli NS, Beesetty Y, Lee W, Washington MK, Chen X, Lockhart AC, et al. Novel mechanistic insights into Ectodomain shedding of EGFR ligands Amphiregulin and TGF-a: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res. 2014;74:2062–72. doi:10.1158/0008-5472.CAN-13-2329.CrossRefPubMedPubMedCentral

15.

Luo G, Long J, Qiu L, Liu C, Xu J, Yu X. Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: A Meta-analysis. Pancreatology. 2011;11:595–600. doi:10.1159/000334465.CrossRefPubMed

16.

Handra-Luca A, Hammel P, Sauvanet A, Lesty C, Ruszniewski P, Couvelard A. EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins. J Clin Pathol. 2014;67:295–300. doi:10.1136/jclinpath-2013-201662.CrossRefPubMed

17.

Funatomi H, Itakura J, Ishiwata T, Pastan I, Thompson SA, Johnson GR, et al. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer. 1997;72:512–7. doi:10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C.CrossRefPubMed

18.

Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011;12:104–17. doi:10.1038/nrm3048.CrossRefPubMed

19.

Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280:5350–70. doi:10.1111/febs.12393.CrossRefPubMed

20.

Saikali S, Avril T, Collet B, Hamlat A, Bansard J, Drenou B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol. 2006;81:139–48. doi:10.1007/s11060-006-9220-3.CrossRefPubMed

21.

Heimberger AB, Hlatky R, Suki D. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11:1462–6. doi:10.1158/1078-0432.CCR-04-1737.CrossRefPubMed

22.

Addison CL, Ding K, Zhao H, Le Maître A, Goss GD, Seymour L, et al. Plasma transforming growth factor-α and amphiregulin protein levels in NSCLC Clinical Trials Group. J Clin Oncol. 2010;21:5247–56.CrossRef

23.

Ishikawa N, Daigo Y, Takano A. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005;65:9176–84. doi:10.1158/0008-5472.CAN-05-1556.CrossRefPubMed

24.

Masago K, Fujita S, Hatachi Y, Fukuhara A, Sakuma K, Ichikawa M, et al. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci. 2008;99:2295–301. doi:10.1111/j.1349-7006.2008.00931.x.CrossRefPubMed

25.

Fontanini G, De Laurentiis M, Vignati S, Chinè S, Lucchi M, Silvestri V, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998;4(1):241–9.PubMed

26.

Kleeff J, Friess H, Berberat PO, Martignoni ME, Z’graggen K, Büchler MW. Pancreatic cancer—new aspects of molecular biology research. Swiss Surg. 2000;6:231–4. doi:10.1024/1023-9332.6.5.231.CrossRefPubMed

27.

Chen Z, Chen J, Gu Y, Hu C, Li J, Lin S, et al. Aberrantly activated AREG–EGFR signaling is required for the growth and survival of CRTC1–MAML2 fusion-positive mucoepidermoid carcinoma cells. Oncogene. 2014;33:3869–77. doi:10.1038/onc.2013.348.CrossRefPubMed

28.

So WK, Fan Q, Lau MT, Qiu X, Cheng JC, Leung PC. Amphiregulin induces human ovarian cancer cell invasion by down-regulating E-cadherin expression. FEBS Lett. 2014;588(21):3998–4007. doi:10.1016/j.febslet.2014.09.017. Epub 2014 Sep 23.CrossRefPubMed

29.

Saeki M, Egusa H, Kamano Y, Kakihara Y, Houry WA, Yatani H, et al. Exosome-Bound WD repeat protein monad inhibits breast cancer cell invasion by Degrading Amphiregulin mRNA. PLoS One. 2013;8(7):e67326. doi:10.1371/journal.pone.0067326.CrossRefPubMedPubMedCentral

30.

Higginbotham JN, Demory Beckler M, Gephart JD, Franklin JL, Bogatcheva G, Kremers GJ, et al. Amphiregulin exosomes increase cancer cell invasion. Curr Biol. 2011;21(9):779–86. doi:10.1016/j.cub.2011.03.043. Epub 2011 Apr 21.CrossRefPubMedPubMedCentral

Title: Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma
Authors: Li Wang
Huanwen Wu
Lili Wang
Junliang Lu
Huanli Duan
Xuguang Liu
Zhiyong Liang
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2016
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-016-0512-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis

Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer

Retraction note: A histopathological analysis of the epidemiology of coronary atherosclerosis: an autopsy study

Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression

Apocrine mixed tumor of the eyelid: a case report

Occurrence and detection method evaluation of group B streptococcus from prenatal vaginal specimen in Northwest China